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Abstract
Background: Platelet activation is crucial in normal hemostasis. Using a clotting system free of
external tissue factor, we investigated whether activated Factor VII in combination with platelet
agonists increased thrombin generation (TG) in vitro.
Methods and results: TG was quantified by time parameters: lag time (LT) and time to peak
(TTP), and by amount of TG: peak of TG (PTG) and area under thrombin formation curve after 35
minutes (AUC→35min) in plasma from 29 healthy volunteers using the calibrated automated
thrombography (CAT) technique. TG parameters were measured at basal conditions and after
platelet stimulation by sodium arachidonate (AA), ADP, and collagen (Col). In addition, the effects
of recombinant activated FVII (rFVIIa) alone or combined with the other platelet agonists on TG
parameters were investigated. We found that LT and TTP were significantly decreased (p < 0.05)
and PTG and AUC→35min were significantly increased (p < 0.05) in platelet rich plasma activated
with AA, ADP, Col, and rFVIIa compared to non-activated platelet rich plasma from normal
subjects (p = 0.01). Furthermore platelet rich plasma activated by the combined effects of rFVIIa
plus AA, ADP or Col had significantly reduced LT and TTP and increased AUC→35min (but not
PTG) when compared to platelet rich plasma activated with agonists in the absence of rFVIIa.
Conclusion: Platelets activated by AA, ADP, Col or rFVIIa triggered TG. This effect was increased
by combining rFVIIa with other agonists. Our intrinsic coagulation system produced a burst in TG
independent of external tissue factor activity an apparent hemostatic effect with little thrombotic
capacity. Thus we suggest a modification in the cell-based model of hemostasis.
Background
Tissue factor (TF) exposed after endothelial injury binds
FVIIa to initiate thrombin generation (TG). In addition
Factor VIIa on surface of platelets may cause TG in the
absence of TF involvement [1,2]. In this process the trans-
bilayer movement of phosphatidylserine through the flip-
flop mechanism [3,4] likely provides the necessary proco-
agulant phospholipid surface. Thus platelets play a role in
thrombin formation and thrombin is a potent platelet
activator. Platelets that adhere to the exposed subendothe-
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lium [5] after endothelial injury, are influenced by a
number of different agonists in addition to thrombin.
One can readily imagine that such agonists not only influ-
ence platelet adherence and aggregation but also
thrombin generation.
Indeed we showed previously that platelets stimulated by
arachidonic acid (AA) significantly increased TG by the
intrinsic clotting pathway independent of external TF [6].
In platelet rich plasma (PRP) from healthy subjects, ADP
accelerated and enhanced TF induced TG via stimulation
of P2Y12 receptors [7].
One controversial issue is whether TF is present in plate-
lets and/or circulates in blood in the form of cell-derived
microparticles [8,9]. Although platelets could not con-
tains TF, they can generate thrombin through a TF inde-
pendent mechanism [2]. Because TF expression by
vascular cells induces intravascular thrombosis [9], in this
study, we used an intrinsic coagulation system, lacking
external TF. We examined whether platelet activation by
well- known platelet activators (sodium arachidonate,
ADP, or collagen (Col)) influences TG induced in PRP by
recombinant activated FVII (rFVIIa), a pathway relevant to
the hemostatic process.
Materials and methods
Subjects
Twenty nine healthy volunteers, 20 women and 9 men
ages 22 to 72, without a history of thromboembolic, hem-
orrhagic, or other known disease consented to participate
in the study. The volunteers agreed to refrain from taking
any drug for 10 days prior to venapucture.
An additional group of 30 healthy volunteers with similar
basal characteristics was studied using low platelet ago-
nists concentrations.
An informed consent was obtained from all volunteers
before joining the study. Only subjects with a normal pro-
thrombin time and activated partial thromboplastin time
were included in the study. To confirm the absence of any
drug affecting platelet function, platelet aggregation in
PRP was measured photometrically in a double-channel
Lumi-Aggregometer (Chrono-log Corp., Havertown,
PA,USA.). Any volunteers showing an abnormal platelet
aggregation response to AA or ADP, was discarded from
the study.
Reagents
Fluorogenic thrombin substrate, Z-Gly-Gly-Arg-AMC,
(Bachem, Switzerland) was dissolved in DMSO at a con-
centration of 100 mmol/l. A stock solution was prepared
containing 100 mmol/l fluorogenic substrate, 1 mol/l cal-
cium chloride and Fluo Buffer (20 mmol/l HEPES, pH
7.35 containing 60 mg/ml bovine serum albumin (Sigma,
St Louis MO, USA)). For TG assays, a working solution
containing 2.5 mmol/l fluorogenic substrate, 100 mmol/
l CaCl2 and 2.5% (v/v) DMSO was used.
Platelet activation agents used in the TG assay were 1) ara-
chidonic acid (AA), sodium salt (from Biopool Ventura,
Ca, USA), 0.625 and 0.125 mmol/L; 2) ADP (Sigma, St.
Louis, MO, USA), 2 µmol/L; 3) collagen (collagen reagent
Horm, from Dipro, Austria) 0.5 µg/ml; and 4) recom-
binant activated Factor VII (Novo Seven, NovoNordisk,
Bagsværd, Denmark) generous gift from NovoNordisk,
Argentina.
Preparation of plasma
Venous blood was withdrawn from the antecubital vein
without stasis and mixed with 0.11 mol/L sodium citrate
(1:10 v/v). Platelet rich plasma (PRP) was obtained by
centrifugation at 900 rpm for 10 minutes at room temper-
ature and platelet poor plasma (PPP) was obtained by
centrifuging PRP at 4000 rpm for 10 minutes. PRP was
adjusted to a platelet count of 290,000/µL to 310,000/µL
with autologous PPP. If contamination of PRP with eryth-
rocytes or leukocytes was observed by light microscopy, a
second centrifugation at 900 rpm for 5 minutes was con-
Table 1: Activating effect of agonists on Lag Time.
Assay System N-PRP plus Lag Time (minutes) mean ± SD
BC D E F G H
Saline rFVIIa 5 µg/mL p value B vs C rFVIIa 2.6 µg/mL P value B vs E rFVIIa 0.5 µg/mL p value B vs G
1. Saline 17.1 ± 5.1 7.9 ± 2.1 <0.001 8.2 ± 2.4 <0.001 9.0 ± 1.9 <0.001
2. ADP 2 µM 11.5 ± 3.0 7.2 ± 2.0 <0.001 7.6 ± 1.6 <0.001 8.1 ± 2.0 <0.001
3. Col 0.5 µg/mL 11.9 ± 3.1 7.0 ± 2.8 <0.001 7.9 ± 2.8 <0.001 8.4 ± 2.9 <0.001
4. AA 0.625 mmol/L 8.4 ± 2.0 5.9 ± 1.2 <0.05 6.2 ± 1.3 <0.05 6.8 ± 1.3 <0.05
5. AA 0.125 mmol/L 9.5 ± 2.7 6.5 ± 1.5 <0.05 7.0 ± 1.8 <0.05 7.3 ± 1.7 <0.05
Parameters of TG in PRP from 29 normal volunteers. Effect of ADP, collagen (Col); sodium arachidonate (AA) and rFVIIa at different 
concentrations.
Column B:1 vs 2 to 5 p < 0.01 Column C: 1 vs 4 and 5 p < 0.01; Column E. 1 vs 4 and 5 p < 0.005 for both; Column G. 1 vs 4 and 5 p < 0.01 for 
both.Thrombosis Journal 2006, 4:5 http://www.thrombosisjournal.com/content/4/1/5
Page 3 of 8
(page number not for citation purposes)
ducted to minimize the number of these cells. Plastic
syringes, tubes, and pipettes were used for all tests.
Thrombin generation study
TG was assayed by the calibrated automated thrombogra-
phy (CAT) technique essentially as described by Hemker
et al [10]. An intrinsically triggered coagulation system
was used in which platelets of PRP were activated with AA,
ADP, Col, alone or in combination with rFVIIa. PRP and
agonists were incubated for 10 minutes before adding
rFVIIa and conducting the assay. Samples were assayed in
round bottom polypropylene microtiter plates (Greiner
Labortechnik, Germany) using a microtiter plate fluorom-
eter (Fluoroskan Ascent reader, Thermo Labsystems Hel-
sinki, Finland). Tests were run within 88 ± 24 minutes of
blood collection.
The assay system consisted in 80 µL of PRP and 20 µL of a
solution that brought the test mixture to a final concentra-
tion of 0.625 mmol/L and 0.125 mmol/L AA, 2 µM ADP,
0.5 µg/ml, collagen or 5, 2.6, 0.5, or 0.25 µg/mL rFVIIa.
The fluorogenic substrate working solution was used to
start the reaction. Fluorescence was measured at 15 sec-
ond intervals over a period of 50 minutes. Each sample
was assayed simultaneously in quadruplicate.
Platelet activation is a very sensitive process and activation
during blood withdrawn or PRP preparation could affect
the final results. To exclude this bias, experiments in
which the lag time of thrombin generation was less than
1 S.D. shorter than the mean, were discarded.
Definitions used
Lag-time (LT): the time in minutes from the start of the
assay to the initial generation of thrombin (the moment
at which 10 nM thrombin is formed).
Time to peak of thrombin generation (TTP): the time in
minutes required to reach maximum thrombin genera-
tion (TG).
Peak of thrombin generation (PTG): the maximum
thrombin concentration expressed in nmol/L.
Endogenous Thrombin Potential (ETP): area under the
curve (AUC) expressed in nmol/L of thrombin [11]. ETP
was calculated and corrected for α2  macroglobulin-
thrombin complex activity using thrombinoscope soft-
ware, Maastricht, Netherlands considering the start tail at
35 minutes (AUCo→35min.)
Statistical analysis
The nature of the quantitative variables distribution was
assessed by the Shapiro-Wilk test. Quantitative variables
are expressed as mean ± standard desviation (SD). Differ-
ences among groups of data were explored through
repeated measures ANOVA or Friedman tests according to
the distribution. The Student-Newman-Keuls test and its
"by ranks" version were used in the post hoc analyses. p <
0.05 (two tailed) were considered as significant.
CSS/Statistica, v.4.3, 1993, Software (StatSoft, Tulsa, USA)
was used for analyses.
Results
Time parameters (LT and TTP)
In normal PRP activated by a high or low AA concentra-
tions, a significant decrease in LT to TG was observed
(Table 1). Likewise activation by ADP or Col significantly
decreased LT but to a lesser extent than AA (Table 1). In
addition, significant decreases in TTP of TG were observed
in normal PRP activated by different agonists (Table 2).
Because LT is a part of TTP the observed decreases in TTP
likely result from the agonists effects on LT.
Table 2: Activating effect of agonists on Time to Peak
Assay System N-PRP plus TTP (minutes) mean ± SD
BC D E F G H
Saline rFVIIa 5 µg/mL p value B vs C rFVIIa 2.6 µg/mL P value B vs E rFVIIa 0.5 µg/mL P value B vs G
1. Saline 21.8 ± 3.9 14.3 ± 3.1 <0.001 15.1 ± 3.2 <0.001 16.5 ± 3.2 <0.001
2. ADP 2 µM 16.8 ± 3.5 13.4 ± 2.8 <0.01 13.8 ± 2.4 <0.01 13.9 ± 3.0 <0.01
3. Col 0.5 µg/mL 16,6 ± 3.4 12.5 ± 3.2 <0.05 13.5 ± 3.1 <0.01 13.3 ± 3.1 <0.01
4. AA 0.625 mmol/L 13.5 ± 2.8 12.0 ± 2.2 NS 12.1 ± 2.6 NS 12.2 ± 2.5 NS
5. AA 0.125 mmol/L 14.6 ± 3.5 12.7 ± 2.6 NS 13.1 ± 2.7 NS 12.9 ± 2.5 NS
Parameters of TG in PRP from 29 normal volunteers. Effect of ADP, collagen (Col); sodium arachidonate (AA) and rFVIIa at different 
concentrations.
Column B:1 vs 2 to 5 p < 0.001 for all. Column C 1 vs 4 p = 0.05
Column E: 1 vs 4, 5 p < 0.01 and <0.05; Column G: 1 vs 2 to 5 p < 0.01.Thrombosis Journal 2006, 4:5 http://www.thrombosisjournal.com/content/4/1/5
Page 4 of 8
(page number not for citation purposes)
Different concentrations of rFVIIa produced a significant,
dose-dependent decreases in LT (Table 1). The highest
dose of rFVIIa was more efficient in decreasing LT than
any of the other agonists' (Table 1). In combination with
other agonists rFVIIa significantly decreased LT compared
to each agonist alone (Table 1, columns D,F,H). In con-
trast to AA, which significantly decreased LT in the pres-
ence of rFVIIa, ADP and Col did not significantly augment
the effect of rFVIIa alone (Table 1, column C, E, G). In
combination with ADP or Col, but not AA, rFVIIa further
decreased TTP compared to ADP or Col alone (Table 2).
Amount parameters (PTG and AUCo→35min)
As is shown in Tables 3 and 4, all of the tested activators
increased both the peak of TG and the AUCo→35min to sig-
nificantly higher levels than observed for the saline con-
trol. Because there is a natural upper limit to both PTG
and AUCo→35min values, it makes sense that, in general,
we did not observe a dose dependency for rFVIIa further
significant increase when one potent activator was added
to another (Tables 3 and 4). Only the lowest concentra-
tion of rFVIIa increased PTG of the other agonists with the
exception of the lower amount of AA (Table 3). Although
there was an apparent tendency for higher TG using the
lower AA concentration than for the higher concentration,
differences were not statistically significant.
From these results it follows that a synergistic effect of acti-
vators can only be observed using suboptimal activator
doses. Therefore the effects of combining low amounts of
agonists were also tested (Table 5). We found that, at the
concentrations tested, ADP or Col had no additive effect
to that of AA alone. A low concentration of recombinant
tissue factor (TF) was more effective in shortening TG time
parameters but not amount parameters, than any agonist
alone or in combination.
Comparison of the intrinsic clotting system with rTF-mediated clotting
The amount of TF exposed after blood vessel wall injury is
unknown, as is the contribution of soluble TF. However,
it is probably much lower than the amount classically
employed in tests of the Quick-time type. We arbitrarily
used a rTF concentration of 2.5 pmol/L and compared its
effects to the combined activity of AA at two concentra-
tions plus rFVIIa. As shown in figure 1 the effects on TG
were of the same order of magnitude.
Table 4: Activating effect of agonists on Area under the curve (AUCo→ 35min ).
Assay System N-PRP plus AUC (nmol/L) mean ± SD
BC D E F G H
Saline rFVIIa 5 µg/mL p value B vs C rFVIIa 2.6 µg/mL P value B vs E rFVIIa 0.5 µg/mL P value B vs G
1. Saline 934 ± 431 1770 ± 411 <0.001 1661 ± 363 <0.001 1850 ± 327 <0.001
2. ADP 2 µM 1523 ± 364 1873 ± 366 <0.05 1773 ± 349 <0.05 2078 ± 437 <0.01
3. Col 0.5 µg/mL 1430 ± 470 1883 ± 433 <0.01 1766 ± 384 <0.05 2032 ± 502 <0.01
4. AA 0.625 mmol/L 1520 ± 373 1711 ± 410 NS 1726 ± 404 NS 1934 ± 408 <0.01
5. AA 0.125 mmol/L 1754 ± 374 1991 ± 372 NS 1872 ± 355 NS 2115 ± 403 <0.01
Parameters of TG in PRP from 29 normal volunteers. Effect of ADP, collagen (Col); sodium arachidonate (AA) and rFVIIa at different 
concentrations.
Column B:1 vs 2 to 5 p < 0.01 for all. Column G: 1 vs 5 p < 0.01
Table 3: Activating effect of agonists on Peak of TG (PTG).
Assay System N-PRP plus PTG (nmol/L) mean ± SD
BC D E F G H
Saline rFVIIa 5 µg/mL p value B vs C rFVIIa 2.6 µg/mL P value B vs E rFVIIa 0.5 µg/mL P value B vs G
1. Saline 97 ± 36 160 ± 36 <0.001 151 ± 42 <0.001 189 ± 42 <0.001
2. ADP 2 µM 156 ± 50 178 ± 49 NS 167 ± 45 NS 214 ± 70 <0.01
3. Col 0.5 µg/mL 158 ± 60 180 ± 45 NS 174 ± 46 NS 215 ± 63 <0.01
4. AA 0.625 mmol/L 160 ± 43 164 ± 42 NS 172 ± 49 NS 204 ± 59 <0.01
5. AA 0.125 mmol/L 191 ± 52 193 ± 52 NS 184 ± 49 NS 222 ± 69 NS
Parameters of TG in PRP from 29 normal volunteers. Effect of ADP, collagen (Col); sodium arachidonate (AA) and rFVIIa at different 
concentrations.
Column B:1 vs 2 to 5 p < 0.001 for all Column C 1 vs 5 p < 0.01, Column E: 1 vs 5 p < 0.05Thrombosis Journal 2006, 4:5 http://www.thrombosisjournal.com/content/4/1/5
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Discussion
Previously we found that AA-stimulation of platelets sig-
nificantly increases TG in normal PRP by a pathway inde-
pendent of external TF, shortening the LT and increasing
the amount of thrombin formed [6]. Using the calibrated
automated thrombography (CAT) technique [10] the
present results confirms this finding and show that Col,
ADP and rFVIIa also increase TG as measured by time (LT
and TTP) and thrombin concentration (PTG and AUC)
parameters. AA alone or combined with rFVIIa, was more
effective in shortening time parameters than other ago-
nists (Table 1 and 2) but all agonists similarly produced a
small increase of amount parameters (Tables 3 and 4).
Because the physiological concentrations of ADP, Col and
AA at the site of a lesion are unknown we hesitate to draw
conclusions on the relative importance of these activators
in vivo.
It must be taken into account that there is a natural upper
limit to TG amount parameters and a natural lower limit
to the time parameters. Therefore the potentiating effect
of a second agonists is difficult to observe if the first ago-
nist is already present in near optimal amounts. Neverthe-
less, potentiating effects were not observed even when low
amounts of agonists were tested (Table 5).
We can speculate that the combined effect of AA and
rFVIIa in the current system independent of external addi-
tion of TF resembles the effect of TF. Since the lower
amount of AA plus rFVIIa was more effective in shortening
the time parameters and in increasing the amount param-
eters than the higher amount of AA, it could be supposed
that AA in combination with rFVIIa, has a concentration-
dependent effect. (figure 1).
Because results were similar when ADP, Col, AA or rFVIIa
were used at low agonists concentrations (Table 5), it is
possible that the agonists and rFVIIa act through a com-
mon pathway. However other possibilities are also feasi-
ble: 1st. relative concentrations of activators and platelet
receptors are important. 2nd. there is competition for
platelets receptors between ADP/AA or Col/AA. Moreover
there is not synergism between rFVIIa and the other acti-
vators since increased rFVIIa concentration alone or
together with a fixed concentration of another agonist
produced rFVIIa dose dependent activation.
Lisman et al [12] proposed that platelets are activated by
collagen resulting in the exposure of procoagulant phos-
pholipid surface. High-dose rFVIIa subsequently binds to
the activated platelet, culminating in thrombin genera-
tion. In addition to Col, we found that AA and ADP are
capable of activating platelets. Furthermore platelet acti-
vation could be accomplished by rFVIIa alone or in com-
bination with another agonist.
Thus, the results obtained in the present in vitro studies,
suggest that a burst in TG mediated by FVIIa plus other
agonists independent of external TF may be important in
normal hemostasis.
Whether this TG is independent of possible TF encrypted
(not procoagulant) in platelets is beyond the scope of the
current experiments. After undergoing the flip-flop mech-
anism, phosphatidylserine could cause decryption of
platelet TF and may contribute to local hemostasis, but
the potential importance of this activity is not well
defined [13]
Table 5: Effect of pair of agonists compared with single agonist in thrombin generationparameters (n = 30) using low doses agonists 
and rTF. Final concentration of agonists: ADP 0.2 µM; sodium arachidonate (AA) 0.125 mmol/L; collagen (Col) 0.05 µg/mL, 
recombinant tissue factor (rTF) 2.5 pmol/L
BC D E
Lag Time (min.) mean ± SD Time to Peak (min.) mean ± SD PTG (nmol/L) mean ± SD AUC (nmol/L) mean ± SD
1 ADP 15.4 ± 4.0 23.2 ± 4.9 155 ± 41 1260 ± 474
2. AA +ADP 11.3 ± 2.5 17.3 ± 2.6 198 ± 45 1604 ± 188
3. Col 14.3 ± 3.3 21.6 ± 3.7 148 ± 44 1392 ± 264
4. AA+Col 11.8 ± 2.5 17.8 ± 3.3 187 ± 53 1551 ± 257
5. AA 12.9 ± 3.1 19.0 ± 3.4 179 ± 58 1488 ± 286
6. rTF 5.8 ± 1.8 12.9 ± 2.4 154 ± 50 1495 ± 337
Parameters of TG in PRP from 30 normal volunteers. PTG: Peak to thrombin generation. AUC: Area under the curve. AA, ADP or Col were 
compared with their combining effects. Also rTF, 2.5 pM was compared with the other agonists.
Lag Time: 1 vs 2 <0.001; 3 vs 4 <0.01; 2 vs 5 = NS; 4 vs 5 = NS 6 vs 1 to 5 <0.001
Time to Peak 1 vs 2 <0.001; 3 vs 4 <0.001; 2 vs 5 = NS; 4 vs 5 = NS 6 vs 1 to 5 <0.001
PTG 1 vs 2 <0.001; 3 vs 4 <0.01; 2 vs 5 =NS; 4 vs 5 =NS 6 vs 1 to 5 =NS
AUCo→35min 1 vs 2 <0.001; 3 vs 4 =NS; 2 vs 5 =NS; 4 vs 5 =NS 6 vs 1 to 5 =NS
rTF appears as more effective than each agonist alone or their combination in shorten times parameters of TG, but effects are not different when 
amount parameters are considered.Thrombosis Journal 2006, 4:5 http://www.thrombosisjournal.com/content/4/1/5
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The burst of thrombin generated on the platelet surface
produces a stable hemostatic clot [14]. As described by
Hemker and Béguin [15] clotting begins when 10–20
nmol/L of thrombin is formed. Even if the initial amount
of thrombin is not affected, the faster initial thrombin
generation caused by agonists could be safe for patients
and important for hemostasis. Clinical experience has
shown a beneficial effect of rFVIIa in controlling bleeding
in patients with various coagulation deficiencies or plate-
let defects [16]. It can be supposed that intravenously
administrated rFVIIa will not act on surfaces devoid of
adhered platelets resulting in enhanced of thrombin gen-
eration only at the site of vascular damage.
Considering our results and others from the literature [17-
19] we can speculate that hemostasis and thrombosis
mechanisms although similar proceed through different
routes: rFVIIa can function via a TF-dependent or inde-
pendent pathway and both pathways are operative in vivo
[20]. Thus, although FVIIa activity is enhanced several-
fold by endothelial exposed TF, external TF is not an abso-
lute requirement since FVIIa can also generate thrombin
on the platelet surface independently of external TF [1,2].
In hemostasis, a small amount of exposed TF will trans-
form FVII into it active form. With the help of agonists
released in situ following platelet deposition on the
wounded endothelium, FVIIa activates platelets and
induces the membrane flip-flop mechanism. This leads to
thrombin generation (first explosion) and local fibrin for-
mation. The local clotting mechanism is limited by several
factors: 1) dilution of activators in the bloodstream of a
non occluded vessel; 2) a small amount of exposed TF in
a relatively minor area of the wall lesion; 3) local inhibi-
tion of TF/FVIIa activity by tissue factor pathway inhibitor.
4) Limitation of clot extension by plasmatic inhibitors
and 5) Limitation of clot lysis by platelet plasminogen
activator inhibitor. Our model of hemostasis is in line
with the cell-based model of coagulation [2,19] but the
effects of agonists and their combined activities with FVIIa
are included because they seem to be important in normal
hemostasis (figure 2). In arterial thrombosis, mainly
located on atheroma, inflammation promotes plaque
rupture [21,22] and increases TF expression in endothelial
cells and monocytes. The amount of TF bound to FVII (TF/
FVIIa complex) is several times greater [15,23] than that of
TF/FVIIa complex formed in a wounded vascular wall, and
with platelet it causes a burst of thrombin formation (sec-
ond explosion). Partial or total occlusion of the blood ves-
sel, stasis and activation of blood clotting proteins and
platelets and artery diameter, are parameters that prevent
dilution of activated factors and generated thrombin.
These parameters together with platelet-erythrocyte inter-
actions [24] promote thrombus growth. Increased func-
tional TAFI levels, resulting in decreased fibrinolysis,
induce a more stable thrombotic plug and are associated
with the risk of arterial thrombosis [25].
A practical point related to antithrombotic therapies
arises. Increased concentrations of old or localized effects
of new antithrombotic drugs will affect thrombosis as
well as hemostasis but, because the latter is a weaker proc-
ess, any increase in anticoagulant potential will produces
a bleeding tendency before inhibiting thrombosis [26].
In conclusion, platelets activated by ADP, collagen or AA
triggered TG in PRP. This effect was increased by the addi-
tion of rFVIIa. Although results of the current study can-
not be directly extrapolated to patients, our findings allow
speculation on the roles of platelet agonists and activated
FVIIa in hemostasis and could provide new insights into
antithrombotic therapies [27].
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Effects of recombinant tissue factor (rTF) compared with  sodium arachidonate (AA) at 2 concentrations (0.625 mmol/ L and 0.125 mmol/L) plus recombinant activated FVII (rFVIIa)  on thrombin generation parameters Figure 1
Effects of recombinant tissue factor (rTF) compared with 
sodium arachidonate (AA) at 2 concentrations (0.625 mmol/
L and 0.125 mmol/L) plus recombinant activated FVII (rFVIIa) 
on thrombin generation parameters. Figure according to 
results of Table 1 to 4, lines 4 and 5, column C and Table 5, 
line 6, columns B to E. Concentration of rFVIIa: 5 µg/ml add 
after 10 minutes of PRP incubated with AA at 37°C. AA 
+rFVIIa time parameters (LT and TTP) are similar to those 
obtained by rTF in the indicated concentration. Although 
amount parameters were higher in the combined agonists 
compared with rTF, differences reach statistically significance 
when the lower dose of AA were employed (p < 0.01 and p 
< 0.001 for PTG and AUCo→35min respectively).
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